THERALASE TECHNOLOGIES INC (TLT.CA) Fundamental Analysis & Valuation

TSX-V:TLT • CA88337V1004

Current stock price

0.32 CAD
+0.01 (+3.23%)
Last:

This TLT.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TLT.CA Profitability Analysis

1.1 Basic Checks

  • TLT had negative earnings in the past year.
  • In the past year TLT has reported a negative cash flow from operations.
  • In the past 5 years TLT always reported negative net income.
  • TLT had a negative operating cash flow in each of the past 5 years.
TLT.CA Yearly Net Income VS EBIT VS OCF VS FCFTLT.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M

1.2 Ratios

  • TLT's Return On Assets of -144.90% is in line compared to the rest of the industry. TLT outperforms 60.00% of its industry peers.
  • With a Return On Equity value of -398.40%, TLT perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
Industry RankSector Rank
ROA -144.9%
ROE -398.4%
ROIC N/A
ROA(3y)-132.13%
ROA(5y)-105.29%
ROE(3y)-205.01%
ROE(5y)-152.63%
ROIC(3y)N/A
ROIC(5y)N/A
TLT.CA Yearly ROA, ROE, ROICTLT.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • TLT has a Gross Margin of 55.35%. This is in the lower half of the industry: TLT underperforms 60.00% of its industry peers.
  • TLT's Gross Margin has improved in the last couple of years.
  • TLT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.35%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.53%
GM growth 5Y53.42%
TLT.CA Yearly Profit, Operating, Gross MarginsTLT.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. TLT.CA Health Analysis

2.1 Basic Checks

  • TLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TLT has more shares outstanding
  • Compared to 5 years ago, TLT has more shares outstanding
  • Compared to 1 year ago, TLT has an improved debt to assets ratio.
TLT.CA Yearly Shares OutstandingTLT.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
TLT.CA Yearly Total Debt VS Total AssetsTLT.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • TLT has an Altman-Z score of -10.08. This is a bad value and indicates that TLT is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of TLT (-10.08) is better than 66.67% of its industry peers.
  • A Debt/Equity ratio of 0.19 indicates that TLT is not too dependend on debt financing.
  • TLT has a better Debt to Equity ratio (0.19) than 80.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z -10.08
ROIC/WACCN/A
WACC8.06%
TLT.CA Yearly LT Debt VS Equity VS FCFTLT.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

  • TLT has a Current Ratio of 0.83. This is a bad value and indicates that TLT is not financially healthy enough and could expect problems in meeting its short term obligations.
  • TLT's Current ratio of 0.83 is in line compared to the rest of the industry. TLT outperforms 60.00% of its industry peers.
  • TLT has a Quick Ratio of 0.83. This is a bad value and indicates that TLT is not financially healthy enough and could expect problems in meeting its short term obligations.
  • TLT's Quick ratio of 0.57 is in line compared to the rest of the industry. TLT outperforms 53.33% of its industry peers.
Industry RankSector Rank
Current Ratio 0.83
Quick Ratio 0.57
TLT.CA Yearly Current Assets VS Current LiabilitesTLT.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. TLT.CA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 23.81% over the past year.
  • TLT shows a small growth in Revenue. In the last year, the Revenue has grown by 1.45%.
  • The Revenue has been growing slightly by 1.40% on average over the past years.
EPS 1Y (TTM)23.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)1.45%
Revenue growth 3Y9.8%
Revenue growth 5Y1.4%
Sales Q2Q%-19.6%

3.2 Future

  • The Earnings Per Share is expected to grow by 47.54% on average over the next years. This is a very strong growth
  • TLT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 252.61% yearly.
EPS Next Y39.41%
EPS Next 2Y-10.08%
EPS Next 3Y47.54%
EPS Next 5YN/A
Revenue Next Year13.84%
Revenue Next 2Y27.09%
Revenue Next 3Y252.61%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TLT.CA Yearly Revenue VS EstimatesTLT.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
TLT.CA Yearly EPS VS EstimatesTLT.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.02 -0.02 -0.04

More info and screens

Find the best growth stocksShow best growing peers

1

4. TLT.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • TLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year TLT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLT.CA Price Earnings VS Forward Price EarningsTLT.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLT.CA Per share dataTLT.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0 -0.01 -0.01 -0.02

4.3 Compensation for Growth

  • TLT's earnings are expected to grow with 47.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.08%
EPS Next 3Y47.54%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TLT.CA Dividend Analysis

5.1 Amount

  • TLT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TLT.CA Fundamentals: All Metrics, Ratios and Statistics

THERALASE TECHNOLOGIES INC

TSX-V:TLT (4/20/2026, 7:00:00 PM)

0.32

+0.01 (+3.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-07
Earnings (Next)05-27
Inst Owners0%
Inst Owner ChangeN/A
Ins Owners2.72%
Ins Owner ChangeN/A
Market Cap82.26M
Revenue(TTM)1.00M
Net Income(TTM)-4.35M
Analysts84.44
Price Target0.71 (121.87%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.27%
Min EPS beat(2)-29.45%
Max EPS beat(2)2.91%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)12.22%
Min Revenue beat(2)6.67%
Max Revenue beat(2)17.77%
Revenue beat(4)3
Avg Revenue beat(4)33.52%
Min Revenue beat(4)-55.73%
Max Revenue beat(4)165.37%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20%
EPS NY rev (1m)0%
EPS NY rev (3m)50%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 82.18
P/FCF N/A
P/OCF N/A
P/B 75.27
P/tB 75.27
EV/EBITDA N/A
EPS(TTM)-0.02
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -144.9%
ROE -398.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.35%
FCFM N/A
ROA(3y)-132.13%
ROA(5y)-105.29%
ROE(3y)-205.01%
ROE(5y)-152.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y10.53%
GM growth 5Y53.42%
F-Score4
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.44%
Cap/Sales 9.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.83
Quick Ratio 0.57
Altman-Z -10.08
F-Score4
WACC8.06%
ROIC/WACCN/A
Cap/Depr(3y)14.29%
Cap/Depr(5y)27.96%
Cap/Sales(3y)3.87%
Cap/Sales(5y)8.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y39.41%
EPS Next 2Y-10.08%
EPS Next 3Y47.54%
EPS Next 5YN/A
Revenue 1Y (TTM)1.45%
Revenue growth 3Y9.8%
Revenue growth 5Y1.4%
Sales Q2Q%-19.6%
Revenue Next Year13.84%
Revenue Next 2Y27.09%
Revenue Next 3Y252.61%
Revenue Next 5YN/A
EBIT growth 1Y-1.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.97%
OCF growth 3YN/A
OCF growth 5YN/A

THERALASE TECHNOLOGIES INC / TLT.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of THERALASE TECHNOLOGIES INC (TLT.CA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to TLT.CA.


What is the valuation status for TLT stock?

ChartMill assigns a valuation rating of 1 / 10 to THERALASE TECHNOLOGIES INC (TLT.CA). This can be considered as Overvalued.


Can you provide the profitability details for THERALASE TECHNOLOGIES INC?

THERALASE TECHNOLOGIES INC (TLT.CA) has a profitability rating of 1 / 10.